Nova Eye Medical Limited
ELXMFOTCHealthcare● Active
$0.00
$-0.01(-86.72%)
Market Cap$541249
P/E Ratio—
52W High$0.1
52W Low$0.0019
Nova Eye Medical Limited (ELXMF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ELXMF · earnings · updated Jun 9, 2026
Latest Earnings
Q1 FY2026Report Date: Feb 24, 2026EPS Actual
-$0.01
Est. -$0.00 · -135.6%
Revenue
$0.01B
Est. $0.01B · +1.9%
Fiscal Period
Q1 FY2026
FY ends December
Report Date
Feb 24, 2026
After Market Close
▼ Miss EPS▲ Beat Revenue
ELXMF reports quarterly as a OTC-listed Medical - Devices company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 26, 2026 | — | — | — | — | — | — |
| ▼ Q1 FY2026 | Feb 24, 2026 | -$0.00 | -$0.01 | -135.6% | $0.01B | $0.01B | +1.9% |
| — Q3 FY2025 | Aug 25, 2025 | — | -$0.01 | — | $0.01B | $0.01B | -3.1% |
| ▼ Q1 FY2025 | Feb 21, 2025 | -$0.00 | -$0.01 | -249.8% | $0.01B | $0.01B | +1.8% |
| — Q4 FY2024 | Oct 30, 2024 | — | -$0.01 | — | $0.01B | — | — |
| ◌ Q4 FY2024 | Oct 30, 2024 | — | — | — | — | — | — |
| — Q1 FY2024 | Feb 23, 2024 | — | -$0.02 | — | $0.01B | $0.01B | +0.0% |
| — Q2 FY2023 | Jun 30, 2023 | — | -$0.03 | — | $0.01B | — | — |
Q3 FY2026
Aug 26, 2026
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2026
Feb 24, 2026Miss
EPS Actual
-$0.01
EPS Est.
-$0.00
EPS Surpr.
-135.6%
Revenue
$0.01B
Q3 FY2025
Aug 25, 2025
EPS Actual
-$0.01
EPS Est.
—
EPS Surpr.
—
Revenue
$0.01B
Q1 FY2025
Feb 21, 2025Miss
EPS Actual
-$0.01
EPS Est.
-$0.00
EPS Surpr.
-249.8%
Revenue
$0.01B
Q4 FY2024
Oct 30, 2024
EPS Actual
-$0.01
EPS Est.
—
EPS Surpr.
—
Revenue
$0.01B
Q4 FY2024
Oct 30, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2024
Feb 23, 2024
EPS Actual
-$0.02
EPS Est.
—
EPS Surpr.
—
Revenue
$0.01B
Q2 FY2023
Jun 30, 2023
EPS Actual
-$0.03
EPS Est.
—
EPS Surpr.
—
Revenue
$0.01B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q2 FY2025 | $0.00 | $0.00 | $0.00 | 0 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q2 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q1 FY2026 | Feb 24, 2026 | -135.6% | $0.00 | $0.00 | +0.00% |
| — Q3 FY2025 | Aug 25, 2025 | — | $0.10 | $0.10 | +0.00% |
| ▼ Q1 FY2025 | Feb 21, 2025 | -249.8% | $0.10 | $0.10 | +0.00% |
| — Q4 FY2024 | Oct 30, 2024 | — | $0.10 | $0.10 | +0.00% |
| — Q1 FY2024 | Feb 23, 2024 | — | $0.10 | $0.10 | +0.00% |
| — Q2 FY2023 | Jun 30, 2023 | — | $0.10 | $0.10 | +0.00% |
| — Q4 FY2022 | Dec 31, 2022 | — | $0.13 | $0.13 | +0.00% |
| — Q2 FY2022 | Jun 30, 2022 | — | $0.01 | $0.01 | +0.00% |
Q1 FY2026+0.00%
Report Date
Feb 24, 2026
EPS Beat/Miss
-135.6%
Price Before
$0.00
Price After
$0.00
Q3 FY2025+0.00%
Report Date
Aug 25, 2025
EPS Beat/Miss
—
Price Before
$0.10
Price After
$0.10
Q1 FY2025+0.00%
Report Date
Feb 21, 2025
EPS Beat/Miss
-249.8%
Price Before
$0.10
Price After
$0.10
Q4 FY2024+0.00%
Report Date
Oct 30, 2024
EPS Beat/Miss
—
Price Before
$0.10
Price After
$0.10
Q1 FY2024+0.00%
Report Date
Feb 23, 2024
EPS Beat/Miss
—
Price Before
$0.10
Price After
$0.10
Q2 FY2023+0.00%
Report Date
Jun 30, 2023
EPS Beat/Miss
—
Price Before
$0.10
Price After
$0.10
Q4 FY2022+0.00%
Report Date
Dec 31, 2022
EPS Beat/Miss
—
Price Before
$0.13
Price After
$0.13
Q2 FY2022+0.00%
Report Date
Jun 30, 2022
EPS Beat/Miss
—
Price Before
$0.01
Price After
$0.01
Avg Miss Reaction+0.00%
Beat Rate0 / 8 quarters
Largest Move+0.00% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ELXMF ends December
Nova Eye Medical Limited (ELXMF) most recently reported earnings on February 24, 2026 for Q1 FY2026, posting EPS of $-0.01 — missing the analyst consensus of $-0.00 by -135.6%. The next ELXMF earnings date is expected around September 1, 2026.
Each quarter, investors track ELXMF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ELXMF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ELXMF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ELXMF earnings · 5 questionsNova Eye Medical Limited's next earnings report is expected around September 1, 2026. ELXMF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ELXMF historically reports after market close (AMC).
ELXMF earnings datewhen is ELXMF earningsELXMF next earnings datewhen does ELXMF report earningsELXMF earnings calendar
▸ Source: FMP · Nova Eye Medical Limited SEC filings · US GAAP · Nova Eye Medical Limited SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026